Could an arthritis drug boost leukemia treatment?
NCT ID NCT07392814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests adding tocilizumab, a drug used for arthritis, to standard chemotherapy (azacitidine and venetoclax) for adults with acute myeloid leukemia (AML) who cannot have intensive treatment. The main goal is to find a safe dose and check for side effects. Only 12 people will take part at one hospital in France.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab
What this could lead to
If it works, this could point toward a more effective treatment for AML patients who cannot tolerate intensive chemotherapy.
What could go wrong
This is a very early phase 1 trial with only 12 participants, so safety and dosing are still being figured out. There is no guarantee the combination will work better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, ACUTE MYELOID (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU of Nantes
Nantes, 44000, France